AMG 193 is a potent, selective, and orally bioavailable MTA-cooperative PRMT5 inhibitor. It affects PRMT5-mediated methylation signaling by specifically binding to the PRMT5-MTA complex, effectively inhibiting symmetric dimethylarginine (SDMA) modification and suppressing tumor cell proliferation in MTAP-deleted cancers.
AMG 193 Mechanism of Action: PRMT5 Inhibition in MTAP-Deleted Cancer Cell Research
AMG 193 MOA：Targeting PRMT5/MTA-PRMT5 Complex Pathway for Advanced Solid Tumors